Wrist wearable uses pulses to relieve chronic motion sickness

Chronic motion sickness patients could be helped by the Reliefband, a wearable that uses pulses to block signals entering the part of the brain related to nausea. 

More than 30 million people suffer from chronic motion sickness and experience nausea or vertigo when traveling. The U.S. Food and Drug Administration-cleared Reliefband wearable uses the body’s own neural pathways to control nausea. The wearable delivers pulses to the media nerve at the pressure point at the underside of the wrist. These pulses send signals to the nausea center of the brain to alleviate symptoms for patients.

“Since 2014, the company has demonstrated the viability of our technology in the over-the-counter healthcare market by significantly growing unit and dollar sales,” according to Nick Spring, president and CEO of Reliefband Technologies. “Reliefband Technologies has primarily focused on direct-to-consumer online distribution, and recently, due to uplifting demand has selectively increased distribution in specialty retail environments. Given the rapid increase in wearable technology and consumers desiring to manage their health without medications, new approaches like ours are on the forefront of helping those in need.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.